Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory

British Journal of Pharmacology

Volumn 130, Issue 1, 2000, Pages 33-40

  Schroeder, Ulrike ^a   Schroeder, Helmut ^a   Schwegler, Herbert ^a   Sabel, Bernhard A ^a  

^a Institute of Medical Epidemiology Biometry and Informatics   (Germany)

Author keywords

Binding sites; GABAergic interneurons; Haloperidol; Phencyclidine; Risperidone; Schizophrenia; Short term memory

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BRAIN RECEPTOR; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; GLUTAMATE RECEPTOR; GLUTAMIC ACID; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PARVALBUMIN; PHENCYCLIDINE; RISPERIDONE; SPIPERONE;

AMNESIA; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG RECEPTOR BINDING; HIPPOCAMPUS; INTERNEURON; LEARNING TEST; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SHORT TERM MEMORY;

EID: 0034099269     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703171     Document Type: Article

References (50)

1. ADAMS, B. & MOGHADDAM, B. (1998). Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine. J. Neurosci., 18, 5545-5554.
2. AKBARIAN, S., KIM, J.J., POTKIN, S.G., HAGMAN, J.O., TAFAZZOLI, A., BUNNEY, JR., W.E. & JONES, E.G. (1995). Gene expression for glutamic acid decarboxylase is reduced without loss of neurons of prefrontal cortex of schizophrenics. Arch. Gen. Psychiat., 52, 258-266.
3. BAKSHI, V.P., SWERDLOW, N.R. & GEYER, M.A. (1994). Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther., 271, 787-794.
4. BENES, F.M., MCSPARREN, J., BIRD, E.D., SAN GIOVANNI, J.P. & VINCENT, S.L. (1991). Deficits in small interneurons in prefrontal cortex and cingulate cortices of schizophrenic and schizoaffective patients. Arch. Gen. Psychiatr., 48, 996-1001.
5. BOGERTS, B. (1997). The temperolimbic system of positive schizophrenic symptoms. Schiz. Bull., 23, 423-435.
6. CARLSSON, M. & CARLSSON, A. (1990). Interactions between the glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci., 13, 272-276.
7. CORSO, T.D., SESMA, M.A, TENKOVA, T.I., DER, T.C., WOZNIAK, D.F., FARBER, N.B. & OLNEY, J.W. (1997). Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain. Res., 752, 1-14.
8. COYLE, J.T. (1996). The glutamatergic dysfunction hypothesis for schizophrenia. Harv. Rev. Psychiatry, 2, 241-253.
9. ELLISON, G. (1995). The NMDA antagonists phencyclidine, ketamine and dizocilpine as both behavioral and anatomical models of the dementias. Brain Res. Rev., 20, 250-267.
10. FAUMAN, B.J. & FAUMAN, M.A. (1980). Chronic phencyclidine (PCP) abuse: a psychiatric perspective-part II: psychosis. Psychopharmacol. Bull., 16, 72-73.
11. FILE, S.E. & PELLOW, S. (1985). The effects of trazolobenzodiazepines in two animal tests of anxiety and in the holeboard. Br. J. Pharmacol., 86, 729-735.
12. FLETCHER, G.H. & STARR, M.S. (1985). SKF 38393 and apomorphine modify locomotion and exploration in rats placed on a holeboard by separate actions at dopamine D-1 and D-2 receptors. Eur. J. Pharmacol., 117, 381-385.
13. GALEY, D. & JAFFARD, R. (1992). Post-training medial septal stimulation improves spatial information processing in BALB, c mice. Neurosci. Lett., 143, 87-90.
14. GOLDBERG, T.E. & GOLD, J.M. (1995). Neurocognitive deficits in schizophrenia. In: Hirsch, S.R. & Weinberger, D.R. (eds). Schizophrenia. Blackwell: London. pp 146-162.
15. GOLDMAN-RAKIC, P.S (1991). Prefrontal cortical dysfunction in schizophrenia: Relevance of working memory. In: Carroll, B.J. & Barrett, J.E. (eds). Psychopathology and the brain. Raven: New York. pp 1-23.
16. GRACE, A.A. (1991). Phasic versus tonic dopamine release and the modulation of dopamine system in responsitivity: a hypothesis for the etiology of schizophrenia. Neuroscience, 41, 1-24.
17. HAIK-CREGUER, K.L., DUNBAR, G.L., SABEL, B.A. & SCHROEDER, U. (1998). Small drug sample fabrication of controlled release polymers using the microextrusion method. J. Neurosci. Meth., 80, 37-40.
18. HYDE, J.F. (1992). Effects of phencyclidine on 5-hydroxytryptophan-and suckling-induced prolactin release. Brain Res., 573, 204-208.
19. JENTSCH, J.D., REDMOND JR D.E., ELSWORTH, J.D., TAYLOR, JR., YOUNGREN, K.D. & ROTH, R.H. (1997a). Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science, 277, 953-955.
20. JENTSCH, J.D. & ROTH, R.H. (1999). The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 20, 201-225.
21. JENTSCH, J.D., TRAN, A., LE, D., YOUNGREN, K.D. & ROTH, R.H. (1997b). Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology, 17, 92-99.
22. JONES, K.W., BAUERLE, L.M. & DENOBLE, V.J. (1990). Differential effects of sigma and phencyclidine receptor ligands on learning. Eur. J. Pharmacol., 179, 97-102.
23. KESNER, R.P. & DAKIS, M. (1993). Phencyclidine disrupts acquisition and retention performance within a spatial continuous recognition memory task. Pharmacol. Biochem. Behav., 44, 419 424.
24. KESNER, R.P. & DAKIS, M. (1995). Phencyclidine injections into the dorsal hippocampus disrupt long-but not short-term memory within a spatial learning task. Psychopharmacology. 120, 203-208.
25. KISS, J., BUZSAKI, G., MORROW, J.S., GLANTZ, S.B. & LERANTH, C. (1996). Entorhinal cortical innervation of parvalbumin-containing neurons (basket and chandelier cells) in the rat ammon's horn. Hippocampus, 6, 239-246.
26. KÖHLER, U., SCHRÖDER, H., AUGUSTIN, W. & SABEL, B.A. (1994). A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol releasing polymers. Neurosci. Lett., 170, 99-102.
27. KRYSTAL, J.H., KARPER, L.P., SEIBYL, J.P., FREEMAN, G.K., DELANEY, R., BREMNER, J.D., HENINGER, G.R., BOWERS JR. M.B. & CHARNEY, D.S. (1994). Subanesthetic effects of the noncompetitive NMDA receptor antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiat., 51, 199-214.
28. LISTER, R.G. (1987). Interactions of Ro 15-4513 with diazepam, sodium pentobartibal and ethanol in a holeboard test. Pharmacol. Biochem. Behav., 28, 75-79.
29. LOWRY, O.H., ROSENBROUGH, A.L., FARR, A.L. & RANDALL, R.J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275.
30. MARTIN, P., CARLSSON, M.L. & HJORTH, S. (1998). Systemic PCP treatment elevates brain extracellular 5-HT: A microdialysis study in awake rats. NeuroReport, 13, 2985-2988.
31. MCBAIN, C.J., FREUND, T.F. & MODY, I. (1999). Glutamatergic synapses onto hippocampal interneurons: precision timing without lasting plasticity. Trends Neurosci., 22, 228-235.
32. MURRAY, T.K. & RIDLEY, R.M. (1997). The effect of dizocilpine (MK-801) on conditional discrimination learning in the rat. Behav. Pharmacol., 8, 383-388.
33. OLNEY, J.W. & FARBER, N.B. (1995). NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology, 13, 335-345.
34. OLNEY, J.W. & FARBER, N.B. (1997). Discussion of Bogerts' temporolimbic system theory of paranoid schizophrenia. Schiz. Bull., 23, 533-535.
35. OLNEY, J.W., LABRUYERE, J. & PRICE, M.T. (1989). Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science, 244, 1360-1362.
36. PEARLSON, G.D. (1981). Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. J. Hopkins Med. J., 148, 25-33.
37. ROBERTS, A.C., DESALVIA, M.A., WILKINSON, L.S., COLLINS, P., MUIR, J.L., EUERI, H.B.J. & ROBBINS, T.W. (1994). 6-hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin Card Sort Test: Possible interactions with subcortical dopamine. J. Neurosci., 14, 2531-2544.
38. SAMS-DODD, F. (1995). Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment. J. Neurosci. Meth., 59, 157-167.
39. SAMS-DODD, F. (1996). Phencyclidine-induced stereotyped behavior and social isolation in rats: a possible animal model of schizophrenia. Behav. Pharmacol., 7, 3-23.
40. SAMS-DODD, F. (1997). Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav. Pharmacol., 8, 196 215.
41. SAMS-DODD, F. (1998a). A test predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology, 18, 293-304.
42. SAMS-DODD, F. (1998b). Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology, 19, 18-25.
43. SAMS-DODD, F. (1998c). Effects of dopamine agonists and antagonists on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Psychopharmacology, 135, 182-193.
44. SCHROEDER, U., SCHROEDER, H., DARIUS, J., GRECKSCH, G. & SABEL, B.A. (1998). Simulation of psychosis by continuous delivery of phencyclidine from controlled-release polymer implants. Behav. Brain Res., 97, 59-68.
45. STARR, M.S. (1995). Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse, 19, 264-293.
46. SWERDLOW, N.R, BAKSHI, V.P. & GEYER, M.A. (1996). Seroquel restores sensorimotor gating in phencyclidine-treated rats. J. Pharmacol. Exp. Ther., 279, 1290-1299.
47. TAMMINGA, C.A., KANEDA, H., BUCHANAN, R., KIRKPATRICK, K., THAKER, G.K., YABLONSKI, M.B & HOLCOMB, H.H. (1991). The limbic system in schizophrenia: Pharmacologic and metabolic evidence. In: Tamminga, C.A. & Schulz, S.C. (eds). Advance in Neuropsychiatry and Psychopharmacology, Vol. I: Schizophrenia research. Raven Press Ltd.: New York, pp 99-109,
48. TAMMINGA, C.A., TANIMOTO, K., KUO, S., CHASE, T.N., CONTRERAS, P.C., JACKSON, A.E. & O'DONOHUE, T.L. (1987). PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCP-receptor-acylating agent. Synapse, 1, 497-504.
49. TSAI, G., PASSANI, L.A., SLUSHER, B.S., CARTER, R., BAER, L., KLEINMAN, J.E. & COYLE, J.T. (1995). Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry, 52, 829-836.
50. WOZNIAK, D.F., BROSNON-WATTERS, G., NARDI, A., MCEWEN, M., CORSO, T.D., OLNEY, J.W. & FIX, A.S. (1996). MK-801 neurotoxicity in male mice: Histologic effects and chronic impairments in spatial learning. Brain Res., 707, 165-179.